Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial.
Bottom Line: Progression-free survival was also significantly longer for patients receiving marimastat compared to placebo (P=0.009, hazard ratio=1.32 (1.07-1.63)).Marimastat treatment was associated with the development of musculoskeletal pain and inflammation.This is one of the first demonstrations of a therapeutic benefit for a matrix metalloproteinase inhibitor in cancer patients.
Affiliation: Department of Surgery, Queen Elizabeth Hospital, Birmingham, UK. S.R.Bramhall@bham.ac.ukShow MeSH
Related in: MedlinePlus
Mentions: Analysis of overall survival in the predefined sub-group of patients who had received prior chemotherapy revealed a significant benefit for marimastat at the primary analysis point (P=0.045 log-rank test, HR=1.53 (1.00–2.34)). This survival difference increased with 2 years of additional follow-up (P=0.006 log-rank test, HR=1.68 (1.16–2.44)), with median survival times of 253 days for marimastat and 175 days for placebo, and 2-year survival of 18% and 5% respectively (Figure 2Figure 2
Affiliation: Department of Surgery, Queen Elizabeth Hospital, Birmingham, UK. S.R.Bramhall@bham.ac.uk